Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | C1R | P00736 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959889 | 0.83 | TOP2A (0.61) | GPR35IKBKBHTR3AKCNH2C1R | |
| SCHEMBL2961764 | 0.79 | RCE1 (0.49) | IKBKBMAPTTP53TOP2ADHODH | |
| SCHEMBL7942917 | 0.78 | HTR3A (0.79) | HTR3AKCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2959363 | 0.77 | HTR3A (0.77) | HTR3AKCNH2CYP3A4 | |
| SCHEMBL5639567 | 0.77 | HTR3A (0.79) | HTR3AKCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2959358 | 0.77 | HTR3A (0.77) | HTR3AKCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2955239 | 0.76 | HTR3A (0.78) | HTR3AKCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5247276 | 0.76 | HTR3A (0.55) | HTR3AKCNH2MAPTTP53CYP3A4 | |
| SCHEMBL31048586 | 0.76 | GPR119 (0.54) | IKBKBC1RMAPTTP53ALDH1A1 | |
| SCHEMBL14367753 | 0.74 | TOP2A (0.77) | IKBKBHTR3AKCNH2C1RMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781430-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7307094-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1853597-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR Technology, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089100-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | HTR3E, BRS3, HTR3A | GPR35 161/4885IKBKB 983/4885HTR3A 3/4885 |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | HTR3E, BRS3, HTR3A | GPR35 161/4885IKBKB 983/4885HTR3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.